The Role of TRP Channels in CIPN

STATUS

Recruiting
End date

Sep 30, 2023
participants needed

240
sponsor

Universitaire Ziekenhuizen Leuven

Send

Updated on 4 October 2022

See if I qualify

body mass index

capsaicin

cinnamaldehyde

Accepts healthy volunteers

Summary

Part I:

Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in healthy, male volunteers. In addition, the inter-period and inter-hand reproducibility of the increase in dermal blood flow will be assessed.

Part II:

Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients suffering from chemotherapy-induced peripheral neuropathy compared to matched healthy volunteers.

Part III:

Evaluating the increase in dermal blood flow upon topical application of cinnamaldehyde and capsaicin on the fingers in patients who are treated with paclitaxel or oxaliplatin.

Description

The primary aim is to investigate whether paclitaxel and/or oxaliplatin alter TRP channel functionality in vivo in human. TRP functionality can indirectly be assessed via dermal blood flow changes which are part of the so-called neurogenic inflammation, induced upon TRP activation. In vivo in human, TRP can be activated via topical application of cinnamaldehyde or capsaicin on the skin.

In Part I of the study, the DBF changes upon topical application of cinnamaldehyde or capsaicin on the fingers will be characterized, including inter-period and inter-hand reproducibility.

In Part II, patients who are suffering from chronic CIPN after treatment with paclitaxel or oxaliplatin are included. DBF changes upon cinnamaldehyde and capsaicin are compared to a matched control group.

In Part III, DBF changes are assessed in patients prior to the first administration of taxol/oxaliplatin and at regular points in time during the dosage regimen.

Details

Condition	Chemotherapy-induced Peripheral Neuropathy
Treatment	Cinnamaldehyde, Cinnamaldehyde and capsaicin
Clinical Study Identifier	NCT04415892
Sponsor	Universitaire Ziekenhuizen Leuven
Last Modified on	4 October 2022

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Subject is a white male ≥18 and ≤45 years of age
	Subject is a non-smoker for at least 6 months prior to the start of the study
	Subject has a body mass index between 18-30 kg/m²
	Subject is judged to be in good health on the basis of medical history, physical examination and vital signs
	Subject understands the procedures and agrees to participate in the study by giving written informed consent
	Subject is matched to the patient groups for sex, age and BMI (only part II)
	Inclusion Criteria Patients of Part II
	Subject is a white male or female ≥18 and ≤70 years of age
	Subject is a non-smoker for at least 6 months prior to the start of the study
	Subject has a BMI between 18-35 kg/m²
	Subject has a history of treatment with one of the following chemotherapeutic agents
	Paclitaxel
	Oxaliplatin
	Subject suffers from peripheral neuropathy grade 1, 2 or 3 according to the Total
	Neuropathy Score (clinical version). Grade 1 correlates to a score of 1-7
	Subject suffers from neuropathic symptoms in the upper limbs
	Discontinuation or termination of therapy with the chemotherapeutic agent occurred >1 month and < 1 year ago
	grade 2 to a score of 8-14 and grade 3 to a score of 15-21(10-12)
	Subject understands the procedures and agrees to participate in the study by giving written informed consent
	Inclusion Criteria for patients of Part III
	Subject is a white male or female ≥18 and ≤75 years of age
	Subject is a non-smoker for at least 6 months prior to the start of the study
	Subject has a BMI between 18-35 kg/m²
	Subject will receive treatment with paclitaxel or oxaliplatin in the near future
	Subject understands the procedures and agrees to participate in the study by giving written informed consent
Exclusion Criteria
	Subject has eczema, scleroderma, psoriasis, dermatitis, or keloids, tumors, ulcers, burns, flaps or grafts on their fingers or any other abnormality of the skin which, in the opinion of the investigator may interfere with the study assessments
	Subject has excessive hair growth on the fingers
	Subject cannot avoid excessive tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study
	Subject has a history of significant severe (drug) allergies
	Subject uses any prescription or non-prescription drugs on a regular basis which, in the investigator's opinion, might confound the results of the study
	Subject currently uses lotions, oils, depilatory preparations, makeup, or other topical treatments on the fingers on a regular basis which cannot be discontinued for the duration of the study
	Subject is unable to refrain from drinking alcohol 24 hours prior to each study visit, is currently a regular user of any illicit drugs, or has a history of drug (including alcohol) abuse
	Subject has any of the following vital sign measurements at screening after at least 10 minutes of supine rest: Heart Rate <40 or >100 beats/min, Diastolic Blood Pressure <50 or >90 mmHg, Systolic Blood Pressure <90 or >140 mmHg
	Subject is currently participating or has been involved in testing an investigational drug in another clinical study within the last 4 weeks
	Subject is in a situation or has a condition which, in the opinion of the investigator, may interfere with safe and optimal participation in the study
	Subject has a history of any illness or disorder which, in the investigator's opinion, might confound the results of the study
	Subject suffered from peripheral neuropathy prior to the chemotherapeutic treatment (Only for patients)
	Subject is unable to refrain from drinking caffeinated beverages (e.g. coffee, tea, cola, …) 24 hours prior to each study visit. Subject is unable to limit their intake of caffeinated beverages to ≤4 cups a day throughout the study
	Subject has (a history of) diabetes mellitus, amyloidosis, vitamin B deficiency or any other medical disorder that, in the investigator's opinion, may cause peripheral neuropathy (only for Part II and III)
	Subject has (a history of) a lesion in the central nervous system that is known to possibly cause neuropathic pain: e.g. spinal cord injury, infarction localized in the brainstem or thalamus, syringomyelia, multiple sclerosis, or any other disorder of the CNS that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III)
	Subject has a history of treatment with bortezomib, vincristine, or any other compound that, in the investigator's opinion, may cause neuropathic pain (only for Part II and III)
	Subject did not develop neuropathy after treatment with epirubicine-cyclofosfamide (only for the paclitaxel group in Part III)
	Subject has a family history of peripheral neuropathy (only for Part II and III)

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

body mass index

capsaicin

cinnamaldehyde

Accepts healthy volunteers

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

The Role of TRP Channels in CIPN